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Abstract
The search for protein ligands is a crucial step in the inhibitor design process. Fragment screening represents an interesting
method to rapidly find lead molecules, as it enables the exploration of a larger portion of the chemical space with a smaller
number of compounds as compared to screening based on drug-sized molecules. Moreover, fragment screening usually
leads to hit molecules that form few but optimal interactions with the target, thus displaying high ligand efficiencies. Here
we report the screening of a homemade library composed of 200 highly diverse fragments against the human Peroxiredoxin
5 protein. Peroxiredoxins compose a family of peroxidases that share the ability to reduce peroxides through a conserved
cysteine. The three-dimensional structures of these enzymes ubiquitously found throughout evolution have been
extensively studied, however, their biological functions are still not well understood and to date few inhibitors have been
discovered against these enzymes. Six fragments from the library were shown to bind to the Peroxiredoxin 5 active site and
ligand-induced chemical shift changes were used to drive the docking of these small molecules into the protein structure.
The orientation of the fragments in the binding pocket was confirmed by the study of fragment homologues, highlighting
the role of hydroxyl functions that hang the ligands to the Peroxiredoxin 5 protein. Among the hit fragments, the small
catechol molecule was shown to significantly inhibit Peroxiredoxin 5 activity in a thioredoxin peroxidase assay. This study
reports novel data about the ligand-Peroxiredoxin interactions that will help considerably the development of potential
Peroxiredoxin inhibitors.
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Introduction
The search for new protein ligands is central to chemical
biology and drug discovery. The fragment-based approach
represents an interesting method that combines random screening
and rational structure-based design for the elaboration of bioactive
compounds [1–4]. The method proposed a decade ago by the
Abbott Company to design drugs and inhibitors consists in
screening simple molecules, called the fragments, mostly defined
by their weak molecular weight (,300 Da) [2,3]. Due to the low
complexity of the fragments, the binding affinity of the fragment-
protein complexes are weak, usually in the mM order, in contrast
with the mM activity generally achieved with molecules resulting
from High Throughput Screening [2]. However, screening drug-
sized molecules tends to favor ligands with several sub-optimal
interactions, whereas fragments were shown to exhibit more
favorable binding energies relative to their molecular size, leading
to higher ligand efficiencies [5,6]. As largely demonstrated in the
literature, chemical modifications of these initial fragment hits can
yield very potent molecules [2,4,7,8].
The identification of initial fragments is a critical step for the
success of the approach. In order to validate a fragment as an
interesting starting point, its binding site, binding mode and
binding affinity have to be characterized. Due to the low stability
of the complex, the binding mode of the fragment is particularly
challenging to determine. If X-Ray crystallography represents a
very powerful tool for the resolution of protein-fragment
costructures [9], the method requires high-quality crystals and
highly soluble fragment molecules. Nuclear Magnetic Resonance
(NMR) represents an alternative method where modifications of
NMR parameters upon ligand binding are used to calculate 3D
structures of the complexes [10–12]. However, these methods can
be time-consuming and may be inappropriate for weak and small
ligands such as fragments. Recently, the combination of NMR
data such as ligand-induced chemical shifts and docking
calculations was proposed to rapidly and efficiently obtain
information about the binding site and binding mode of ligands
[13–15].
Our study focuses on the interactions of fragment molecules
with Peroxiredoxins. Peroxiredoxins (PRDXs) constitute a super-
family of enzymes that catalyze the reduction of hydroperoxides
through a conserved catalytic peroxidatic cysteine (Cp) [16–18].
The members of the PRDX family share a highly conserved core
structure derived from the thioredoxin fold, but display important
variations in quaternary structures. If the structural properties of
these proteins have been extensively studied, the enzymatic
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[18–24]. The design of PRDX inhibitors should provide important
information for the understanding of the distinct biological roles of
the PRDX enzymes. To date, few inhibitors or active site ligands
have been discovered for these enzymes. The benzoate was
reported as a ligand of the human Peroxiredoxin 5 protein
(PRDX5), as it was observed in the crystal structure of the protein
[25]. However, no information was published about its affinity
towards the enzyme. More recently, a covalent inhibitor of the
Peroxiredoxin TgPrxII from the parasite Toxoplasma gondii was
published [26].
Here we report for the first time the screening of a homemade
library composed of 200 fragments using ligand-observed NMR
methods on the recombinant human PRDX5 protein. The
backbone NMR resonances of the reduced active form of PRDX5
havebeenassigned,andligand-induced chemical shiftchangeswere
used to drive the docking of the molecules into the protein structure.
Both the binding site and the orientation of the molecule in the
binding pocket were determined for the hit fragments and were
confirmed by the study of fragment homologues. Also, the hit
fragment F152 (catechol) and its homologue, compound D3
(4-methyl-catechol) were shown to inhibit the thioredoxin peroxi-
dase activity of the enzyme. This workpresents novel data about the
ligand-PRDX interactions, and the molecules identified here are
shown to represent interesting starting points for lead generation
against PRDX5.
Results
Elaboration of a fragment library
We previously designed a small generalist library of 60
fragments and used it to elaborate an inhibitor of the Creatine
kinase protein [27], based on the identification of an initial
fragment by NMR screening. Here, the library was enlarged and
contains 200 fragments that correspond to small commercial
compounds with physicochemical properties defined by the rule of
three [28]. The 140 newly added fragments were chosen so as to
enhance the diversity of the library in terms of size, shape and
chemical functionalities. All molecules in 110 mM DMSO-d6 stock
solutions were tested for aqueous solubility (600 mM), purity and
stability by
1H NMR spectra. Waterlogsy experiments were
recorded to detect possible aggregation as LOGSY effects are
characteristic of high molecular weight compounds in water [29].
When the molecules were not soluble at 600 mM, solutions were
tested at 200 mM. If not soluble, the molecules were rejected from
the selection. Then, to optimize the experimental time and to
reduce the protein quantity required for the NMR screening
experiments, fragments were pulled into mixtures of 3 to 6
molecules with minimum spectral overlap. NMR spectra of the
mixtures were recorded after 3 months to confirm the absence of
degradation of the compounds.
NMR screening of the fragment library
The fragment library was tested on the reduced form of PRDX5
by
1H NMR, using both Saturation Transfer Difference (STD)
[30] and Waterlogsy [31] experiments, with experimental
conditions similar to those previously published [27]. The hit
fragments were identified in the mixtures without the need of
deconvolution. Figure 1 shows the NMR spectra recorded on one
of the mixtures, and the identification of fragment F090 as a hit.
Among the 200 fragments, 6 compounds gave strong STD signals
as well as antiphase Waterlogsy effects in the presence of the target
protein, indicating that these 6 fragments bind to PRDX5
(Figure 2). Finally, each hit fragment was tested alone in
interaction with the PRDX5 protein to confirm binding.
Binding affinity measurements
The binding affinities of two of the six hit fragments, F090 and
F152, were determined by measurement of the STD factor
variation upon titration. F152 is the smallest fragment identified
here as a PRDX5 ligand, whereas F090 is the fragment that
induces the strongest STD signals. Figure 3 shows the STD factor
(see experimental section) as a function of the ligand concentration
for F152. A dissociation constant of 3.360.6 mM was calculated
for this fragment as described in the experimental section. For
fragment F090, the binding constant KD was determined to be
1.260.4 mM.
For the four other fragments (F012, F063, F082 and F093), the
solubility in water was too low to obtain reliable measurement.
However, all the hit fragments were ranked according to their
affinity, using their STD factor (fSTD) (Figure 2). The relative degree
of saturation for the individual protons normalized to that of F090
was used to compare the STD effect. We observed that F152 and
F090 respectively display the weakest and strongest STD factor. It
can thus be inferred that the affinity of the six hit fragments lies in
the low millimolar range, likely between 1 and 5 mM.
Docking
To gain insight into the binding site of the fragments, the
molecules were docked into the three-dimensional structure of the
protein using the AutoDock4 program [32,33]. AutoDock4
requires a 3D grid to be defined to represent the protein, and a
Lamarckian genetic algorithm explores positions of the ligand
relative to the grid. Without any knowledge of the binding sites of
the fragments, the docking experiments were done using a box
containing the whole protein and positions were calculated for 50
conformers. As illustrated in Figure 4, seven different binding sites
are proposed by the AutoDock program for fragment F152
(Figure 4.A) and three for fragment F012 (Figure 4.B). Three to six
binding sites were observed for fragments F069, F082, F090 and
F093. For all the fragments, the binding energies of the different
clusters are similar. As an example, the binding energies of F152
vary from 22.98 to 24.37 kcal.mol
21, while the AutoDock
binding energies are estimated to have an error of 2.2 kcal.mol
21
[34]. Moreover, the lowest-energy conformers of the six hit
fragments are not observed in the same binding site, as shown in
Figure 4. Therefore, the docking experiments do not indicate if the
six fragments detected as ligands in the NMR screening bind into
the same binding site and if so, which binding site it is.
NMR assignment of the human PRDX5 backbone
resonances
To go further into the characterization of the fragment binding
site, the backbone resonances of PRDX5 have been assigned.
Triple-resonance NMR experiments recorded on a
15N/
13C/50%
2H-labeled protein sample (see experimental section) were used.
The deuteration was necessary due to the molecular weight of the
protein (dimer of 32 kDa). The backbone assignment was
confirmed with a
15N-edited NOESY experiment through the
characteristic NOEs observed in helices and b-sheets expected
from the 3D crystallographic structure (1HD2 PDB entry [25]).
Characterization of the binding by
15N-HSQC
experiments and docking experiments
To identify the amino acids involved in the protein-ligand
interactions,
15N-HSQC (
15N-Heteronuclear Single Quantum
Fragments Binding to PRDX5
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fragments (10-fold excess). As a result of addition of the
compounds to the
15N-labeled protein, significant chemical shift
perturbations were observed on the NMR protein spectrum (see
supplementary material, Figure S1). Interestingly, the same
PRDX5 residues are affected upon addition of the six fragments.
Those residues belong to the N-terminal part of helix 2 (residues
44 to 49), the N-terminal of helix 3 (residues 78 to 80), the loop
connecting helix 4 to sheet 8 (residues 116 to 120) and the turn
preceding the C-terminal helix (residues 145 to 148) (Figure 5),
and are all located in the active site region. The chemical shift
perturbations mapped on the PRDX5 3D structure clearly show
that the fragments bind to the PRDX5 catalytic site, in close
proximity to the cysteine residue C47 (Figure S2).
As reported previously [35], the knowledge of the ligand
binding site potentially improves the accuracy of the docking
calculations by minimizing the grid volume in the AutoDock
program. Here, the chemical shift changes observed in the
15N-
HSQC experiments were used to define the docking box. Figure 6
shows fragment F152 docked against PRDX5 receptor, using a
box centered on the active site. The 50 structures of F152 were
well superimposed on one cluster into the active site, with a rmsd
of 0.42 A ˚. By comparison, for the blind docking, only 16 positions
out of the 50 docked structures were observed in the active site,
with a rmsd of 1.09 A ˚. The docking results indicate that fragment
F152 docks near the residue T44, in agreement with the NMR
experiments (Figure 5), and highlight the role of the two hydroxyl
function of F152 that point to catalytic cysteine C47 (Figure 6).
Interestingly, the six fragments shown to bind PRDX5 from the
200-fragment library all share a hydroxyl function (see Figure 5).
For all these fragments, a similar feature is observed from the
docking calculations, with the hydroxyl function of the fragments
oriented towards the cysteine C47. These hydroxyl functions
might play a role of a molecular anchor that hangs the ligand to
the PRDX5 protein.
Binding mode analysis of the fragments using fragment
derivatives
To confirm the binding modes of the hit fragments, we have
studied the interactions of PRDX5 with homologues of fragments
Figure 1. Identification of fragment molecule F090 as a ligand of PRDX5 from the NMR experiments. The Waterlogsy (A), STD (B) and
normal
1H1 D( C) spectra (aromatic and ethylenic region) of a mixture of 6 fragments at a 600 mM concentration in presence of 20 mM PRDX5 are
displayed. Only signals of the molecule F090 are observed in the STD experiment whereas the corresponding signals are in antiphase as compared to
all other molecule signals in the Waterlogsy spectrum (framed regions).
doi:10.1371/journal.pone.0009744.g001
Fragments Binding to PRDX5
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hydroxyl function is added in close proximity to the hydroxyl
involved in the interaction with the active site polar region,
whereas in the derivative of F082 (compound D2), the hydroxyl
function is added on the second aromatic ring (Figure 7). The
derivative of F152 was the 4-methyl catechol (compound D3,
represented in Figure 8). According to the NMR data (ligand-
observed as well as protein-observed experiments), compounds
D1, D2 and D3 all bind to the PRDX5 protein, in the same region
as the initial fragments. As illustrated in Figure 7, significant
chemical shift changes are observed when fragment F012 is
compared to compound D1, with the most significant variations
found for residues located around the catalytic cysteine C47
(residues G46, C47, K49 and T50). This indicates that the
additional hydroxyl function is oriented towards those residues, in
agreement with the binding mode observed for F152. By contrast,
the chemical shifts induced by fragment F082 and its derivative
(compound D2) are very similar, with differences smaller than
0.04 ppm (Figure 7). Thus, the addition of the hydroxyl function
in molecule D2 does not strongly modify the binding of the
fragment, showing that the additional oxygen does not play a
crucial role in the interaction with the protein. This is in
agreement with a binding mode where the hydroxyl function
located near the carbonyl of F082 is oriented towards the catalytic
cysteine. The binding mode of F152 is corroborated as well by the
binding of the 4-methyl catechol (compound D3), where the
Figure 3. STD factors (fSTD) of fragment F152 plotted as a
function of ligand concentration for the measurement of the
dissociation constant of the F152-PRDX5 interaction.
doi:10.1371/journal.pone.0009744.g003
Figure 2. Chemical structure and STD factors of the 6 hit fragments of PRDX5 identified by NMR screening. The fragments were tested
for binding by 1D NMR (STD and WaterLOGSY experiments). For each fragment, the STD factor (fSTD) was determined.
doi:10.1371/journal.pone.0009744.g002
Fragments Binding to PRDX5
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of the molecule and interacts with the hydrophobic region of the
active site.
Binding experiments on benzoate and derivatives
In the crystal structure of PRDX5, a benzoate (compound D4)
was found in the active-site pocket of the protein [19,25]. NMR
experiments (STD, Waterlogsy and HSQC) were thus recorded to
study the benzoate-PRDX5 interaction in solution. The three
experiments indicate that the benzoate is a very weak ligand in
solution since only very weak STD signals as well as small
chemical shift variations in the HSQC spectrum were observed, by
comparison to the hit fragments. To go further, we have also
analyzed the interactions of benzoate derivatives with the PRDX5
protein (Figure 8). First, a methyl group was added to the benzoate
(Figure 8.A compound D5) but no interaction was detected by
NMR. Then a hydroxyl function was added to the benzoate and
this fragment (D6) binds to the protein. By substituting the
benzoate carboxyl function for a hydroxyl function, we obtained
the catechol (F152), which binds to the protein as previously
described. The addition of the methyl function to the catechol
(compound D3) does not disturb the interaction. Instead, it seems
to increase the affinity to the PRDX5 protein, according to the
NMR experiments (fSTD=32% and 66% for fragment F152 and
compound D3, respectively). We also tested an aromatic derivative
of the benzoate (compound D7). No interaction was detected,
while substitution of the carboxyl function for a hydroxyl function
leads to a weak ligand (compound D8). As illustrated in Figure 8,
the NMR data show that only the molecules with a hydroxyl
function bind efficiently to the PRDX5 protein in our experimen-
tal conditions.
Inhibition of thioredoxin peroxidase activity
Inhibition of thioredoxin peroxidase activity was assessed with
fragments F012, F069, F082, F090, F093 and F152, and with the
derivative of F152, compound D3. Inhibition measurements were
not possible with fragments F090 and F093 due to insufficient
solubility in the assay, and with fragments F069 and F082
(absorbance at 340 nm). Fragment F012 had no inhibitory activity
(0–600 mM). Fragment F152 and its derivative compound D3
were shown to inhibit the thioredoxin peroxidase activity of
PRDX5 with IC50 values of 10568.5 mM and 2662.2 mM,
respectively (Figure S4).
Discussion
Here we report a study that focuses on the interactions of small
molecules with human PRDX5. To date, few inhibitors have been
discovered for the PRDX family and the only ligand of PRDX5 is
the benzoate anion, which was observed in the active site of the
crystal structure of the enzyme [25]. However, to our knowledge,
no data was available about the dissociation constant or inhibitory
role of this compound. To identify ligands of the enzyme, we
applied the fragment-based methodology [1,2,4,8,9] on the
PRDX5 protein, using our in-house fragment library of 200
molecules. The advantage of screening molecular fragments rather
than drug-sized molecules is that a dramatically larger portion of
chemical structure space is explored with a smaller number of
compounds. Since the fragments are small and much simpler than
drug-like molecules, the fragment methodology enables to discover
molecules which bind more efficiently to a small region of the
protein [6,36].
In the study presented here, the interactions of the fragments
with PRDX5 were analyzed using ligand-observed NMR methods
(STD [30] and Waterlogsy [31]) (Figure 1). Six fragments were
shown to bind the PRDX5 protein among the 200-fragment
library (Figure 2). The six hit fragments were ranked according to
their affinity for PRDX5, using the STD factors (Figure 2 and
Figure 3). The binding affinity was determined for two of the six
ligands, F152 and F090. F152 displays the weakest STD factor and
binds with a 3.360.6 mM affinity to PRDX5, whereas F090 has
the strongest STD factor and a 1.260.4 mM affinity for the
protein. Overall, the affinity of the 6 hit fragments should fall
within a 1–5 mM range.
Figure 4. Surface representation of the PRDX5 protein (code PDB 1HD2) with the lowest-energy fragment conformer for each
cluster calculated by AutoDock. (A) Fragment F152, (B) Fragment F012. The conformer located in the active site pocket of PRDX5 is colored red.
Each cluster is labeled with the average binding energies.
doi:10.1371/journal.pone.0009744.g004
Fragments Binding to PRDX5
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calculations were performed. In this case, the entire protein
surface of the protein is scanned, and scoring functions enable to
identify the binding site. However, as previously reported, it may
be challenging to identify the ligand binding site when the binding
energies of the different positions are similar [35]. Here, for each
fragment, more than three different binding sites were found for
the 50 positions docked into the 3D structure of PRDX5 (Figure 4).
The binding energies of the different clusters are clearly not an
efficient metric to distinguish the ligand binding site since the
binding energy difference falls within the error of the calculations
(2.2 kcal.mol
21) [34]. Therefore, to discriminate the fragment
Figure 5. Weighted average (see experimental section) of the
1H
N and
15N chemical shift changes upon the addition of fragment
F152, F012, F093, F090, F082 and F069, respectively. Only significant modifications (.0.02 ppm) are displayed. The residues showing the
greatest changes are labeled.
doi:10.1371/journal.pone.0009744.g005
Fragments Binding to PRDX5
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PRDX5 chemical shift changes observed upon fragment addition
clearly demonstrate that the six fragments bind to the protein
catalytic pocket near the cysteine residue C47 (Figures 3, 4 and
Figures S1 and S2). These results show that the correct position of
the fragment is not necessarily the lowest-energy conformer of the
docking calculations (Figure 4).
Interestingly, all the six hit fragments share the presence of one
hydroxyl function (see Figure 5). The benzoate anion observed in
the active site of the PRDX5 crystal structure [25] is not reported
as a good PRDX5 ligand in our NMR study. Such observations
are likely due to the difference between the solution state as
compared to the highly-ordered crystal state. The analysis of
benzoate derivatives confirms that the hydroxyl function is an
important feature for the fragments to bind PRDX5 in our
experimental conditions (see Figure 8). To better understand the
role of these hydroxyl functions in the fragment-PRDX5
complexes, binding modes of the fragments were calculated from
docking experiments where the NMR data were used to localize
the fragment binding site. As illustrated in Figure 6, the active site
pocket of PRDX5 is highly dissymmetric with one side strongly
hydrophobic (P40, L112, L116, I119, F120 from chain A and F79
from chain B) whereas the opposite side is polar due to residues
T147, R127, G46 and T44. In the fragment-PRDX5 complexes,
the aromatic part of the fragments interacts with the hydrophobic
side chains of the pocket, whereas the hydroxyl function is oriented
towards the catalytic cysteine and is involved in polar interactions
with main chain or side chain atoms of residues G41, T44, P45,
G46, C47 and R127.
Figure 6 illustrates the binding mode of fragment F152, as
suggested by the docking calculations. One oxygen of F152 makes
contacts with T44 (distance 2.91 A ˚), C47 (3.18 A ˚) and R127
(2.96 A ˚) whereas the second oxygen interacts with P45 (3.80 A ˚)
and G46 (2.98 A ˚). The aromatic ring lies in the hydrophobic
pocket and makes hydrophobic contacts with L116, I119, F120,
and F79. It was interesting to observe the structural similarities of
fragment F152 and the corresponding X-ray conformation of the
benzoate [25]. The two structures superimpose pretty well (0.97 A ˚
rmsd) and the two functions, dihydroxyl for the catechol and
carboxylic for the benzoate, lie in the same site (Figure S3). In the
two structures, the binding motif is represented by two oxygen
atoms that point to the C47 residue. Interestingly, such
interactions roughly mimic the interactions of a peroxidatic
substrate [19,25], even if the O-O distance is here much greater
(2.75 A ˚ for the catechol and 2.24 A ˚ for the benzoate as compared
to 1.54 A ˚ for a peroxidatic substrate).
The binding mode proposed by the combination of NMR
experiments and docking calculations was confirmed by the study
of derivatives of F012, F082 and F152 (Figure 7). The comparison
of the ligand induced chemical shift changes between the ligands
and their derivatives demonstrate that the oxygen atoms point
towards the catalytic cysteine C47. The addition of a methyl group
to F152 (compound D3, Figure 8) corroborates the results, and the
interaction is optimized by increasing the hydrophobicity of the
aromatic part of the molecule. As illustrated in Figure 7, the
molecules with two aromatic rings such as F012 and F082 do not
entirely fit the PRDX5 active site, which is a rather small pocket
(about 9 A ˚ diameter). This could explain the low hit rate (3%)
observed for PRDX5, when compared to other proteins screened
against the same fragment library (unpublished data) and may
suggest that the PRDX5 protein is not highly druggable [37].
To assess the quality of the hit fragments as starting points for
inhibitor design, the ligand efficiencies of F090 (bis-(2-hydro-
xyphenyl)-methan) and F152 (catechol) were determined. Ligand
efficiency is the free energy of binding divided by the number of
heavy atoms [5,6], and is commonly used to predict if a ligand can
potentially be elaborated into a good inhibitor, and to rank hit
compounds in order to choose the best lead molecule. The ligand
efficiencies of F090 and F152 were calculated to be 0.42 kcal.-
mol
21 and 0.26 kcal.mol
21 respectively. In a recent study where
18 highly optimized inhibitors were deconstructed, a nearly linear
relationship was observed between molecular weight and binding
efficiency [38]. It was extrapolated that, considering that the LE is
kept constant during the fragment evolution, a good starting point
should exhibit a LE of 0.3 in order to yield a molecule of
500 g.mol
21 with a IC50,10 nM [39]. These data thus indicate
that fragment F152 represents a very interesting starting point for
the design of a PRDX5 inhibitor. This hypothesis was confirmed
by an enzymatic assay showing that F152 significantly inhibits the
enzymatic activity of PRDX5, with an IC50 value of 10568.5 mM.
The docking calculations suggest that improvement of the
ligand affinities could be achieved through optimization of the
polar contacts with functional group of T144, R139 and T147
(both side chain and main chain). Hydrophobic interaction should
also be strongly strengthened through contacts with L116 and
L112. This hypothesis was confirmed by the analysis of a
derivative of F152, compound D3, which corresponds to the
catechol with an additional methyl moiety. This molecule displays
a stronger STD signal than F152 (fSTD=32% and 66% for F152
and compound D3, respectively). These NMR data were
corroborated by the results of a biochemical assay showing that
the inhibitory activity of F152 is increased by the addition of the
methyl moiety on the phenyl ring (IC50=10568.5 mM and
2662.2 mM for F152 and compound D3, respectively). Another
strategy for optimization of the fragments could be to target both
the active site pocket and an adjacent binding site highlighted by
docking calculation. This second pocket is located at the interface
of the PRDX5 dimer. Here, molecules should be designed to
interact with E83 and S48 side chains.
Figure 6. Binding mode of fragment F152 into the PRDX5
active site. The position of F152 (in magenta) was calculated with the
program AutoDock [32,33]. The residues involved in the active site
pocket are labeled and displayed with sticks. Oxygen atoms, nitrogen
atoms and sulfur atom are colored in red, blue and yellow, respectively.
doi:10.1371/journal.pone.0009744.g006
Fragments Binding to PRDX5
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design of non covalent PRDX inhibitors. However, will it be
possible to design a selective inhibitor for the different PRDXs?
Despite the broad sequence diversity represented among the
different Peroxiredoxin subfamilies, the geometry of the active site
region is rather conserved, with a proline residue (P40), a
threonine residue (T44) and an arginine residue (R127) in van
der Waals contact with the peroxidatic cysteine (C47). Yet, the
three-dimensional structures of PRDX4 (2-Cys Peroxiredoxin,
2PN8 PDB code), PRDX5 (Atypical 2-Cys Peroxiredoxin, 1HD2
PDB code) and PRDX6 (1-Cys Peroxiredoxin, 1PRX PDB code)
show that the quaternary structure dramatically varies among the
subfamilies. As illustrated in Figure 9, the shapes of the PRDX
active sites are modulated by the quaternary structures. PRDX4
and PRDX5 active sites look rather similar whereas the active site
of PRDX6 displays very characteristic features, with a narrow
pocket of ,4A ˚ diameter and ,7A ˚ depth [16]. The bottom of the
PRDX6 cavity is largely hydrophobic while the entry of the pocket
is much more polar due to residues T152 (chain A) and T192
(chain B). By contrast, the active site pocket of PRDX5 is more
cylindrical and less deep. The pocket is dissymmetric with one
hydrophobic side facing a polar region (see above). The overall
shape of the PRDX4 cavity appears to be an oval pocket, with a
hydrophobic patch interrupted by residue H197 while residue
T147 of PRDX5 is replaced in PRDX4 by a hydrophobic residue.
Therefore, in spite of the general idea that the PRDXs share
common active site features, we show here that the pockets differ,
both in their conformation and accessible surface properties.
These significant differences could be used to guide the design of
selective inhibitors. If the molecule F152 is not complex enough to
be a selective fragment, its modification by addition of selected
chemical functions to its phenyl moiety should provide potency as
well as selectivity.
In conclusion, this study reports molecules demonstrated to bind
the PRDX5 active site by NMR experiments and enzymatic
assays. The binding mode of these weak ligands was characterized
by a combination of NMR data and docking calculations and was
confirmed using fragment homologues, highlighting the role of
hydroxyl functions. One fragment, the catechol, was shown to
possess a high ligand efficiency and to exhibit inhibitory activity
against PRXD5, indicating that this molecule is an excellent
starting point for the development of potential PRDX inhibitors.
Figure 7. Comparison of the NMR perturbations between fragments and derivatives. (A) Comparison between fragment F012 and its
derivative (molecule D1), (B) between fragment F082 and its derivative (molecule D2). (1) Difference of the chemical shift perturbations observed
between the fragments and their derivatives. (2) Visualization of the binding modes. The significant NMR perturbations are mapped in the surface of
the PRDX5 structure using blue color.
doi:10.1371/journal.pone.0009744.g007
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Fragment library
The compounds of the library were chosen from Aldrich or
Acros online catalogs with SHAPES-like criteria [40–42] and had
to fit the rule of three [28]. Aqueous solubility was checked for all
compounds by recording
1H 1D NMR spectrum and Waterlogsy
spectrum [31,43]. 110 mM stock solutions of the library
compounds were prepared in DMSO-d6 and conserved at
220uC.
1H 1D NMR spectrum were recorded to check that no
degradation occurs over 3 months. Compounds were mixed by 3
to 6 to decrease the NMR experimental time as well as the protein
quantity. Criteria for the compound selection for the mixtures
were the absence of overlapping resonances in the 1D NMR
spectra. The library contained 200 validated fragments.
Protein production and purification
Human PRDX5 was expressed without its mitochondrial
targeting sequence as a N-terminal 6xHis-tagged protein in E.
coli strain M15 (pRep4) [44]. E. coli were grown at 37uCi nM 9
minimal medium supplemented with thiamine (20 mM) and
containing
15NH4Cl (1 g/L) to produce
15N-PRDX5 or
15NH4Cl
(1 g/L), [
13C6]-D-glucose (4 g/L) and 70:30% (v/v) D2O:H2Ot o
produce
15N/
13C/50%
2H-PRDX5. Recombinant PRDX5 was
purified by affinity chromatography on a Ni
2+-NTA column
(Qiagen) as previously described [44].
NMR screening
All spectra were acquired at 20uC with a Varian Inova
600 MHz NMR spectrometer, equipped with a standard 5 mm
triple-resonance inverse probe with a z-axis field gradient, actively
shielded, and with an autosampler robot. The NMR samples were
prepared with a robot TECAN Miniprep 60. For 175 fragments,
32 NMR tubes were prepared with 20 mM of the reduced protein
and 600 mM fragments. For 25 fragments (6 NMR samples) that
were not soluble at 600 mM in water, the final concentration in the
NMR tube was set to 200 mM. All samples contained 1 mM DTT.
The concentration of DMSO-d6 did not exceed 4% in the NMR
tubes. Control 1D
1H spectra preceded all experiments to assess
the purity and stability of the fragments. NMR screening was
achieved using 1D STD [30] and Waterlogsy [31] experiments.
The parameters used were the same as previously described [27].
All NMR spectra were processed with the Varian VnmrJ software.
KD measurements
Dissociation constants (KD) were obtained for selected com-
pounds by monitoring the STD amplification factors (fSTD)a sa
function of ligand concentration. fSTD were derived from the
equation fSTD=ISTD/I0 * ([L]tot/[PRDX5]tot), where ISTD and I0
are the peak integrals in the STD and 1D
1H experiments
respectively, and [L]tot and [PRDX5]tot are the total concentra-
tions of the ligand and PRDX5, respectively. KD values were
determined by fitting the plot of [L]tot vs. fSTD as previously
published [27].
Docking
AutoDock 4.01 [32,33] with the AutoDockTools graphical
interface was used to simulate 50 different binding conformations
for each PRDX5 ligand. Grid maps were generated with 0.375 A ˚
spacing and set to encompass the residues perturbed upon fragment
addition. The docking calculations were then performed using the
Lamarckian genetic algorithm (LGA) for ligand conformational
searching. The population size was set to 150 and the number of
energy evaluations was 2500000. The 3D structure of PRDX5 was
used (1HD2 PDB entry) and the dimer was built from the
coordinates of the monomer using Makemultimer from the Expasy
Proteomics server (http://expasy.org/tools/).
Backbone resonance protein assignment
NMR samples contained 500 mMo fu n i f o r m l y
15N/
13C/50%
2H
labeled reduced PRDX5 in 10 mM phosphate buffer, 3 mM KCl,
140 mMNaCl pH 7.45 and 2 mMDTT. 3D HNCA, HN(CO)CA,
HNCACB and CBCA(CO)NH experiments from the Varian
Protein Pack were recorded at 28uC on a Varian Inova 600 MHz
Figure 8. Binding experiments on benzoate and derivatives. (A) No binding or very weak binding detected by NMR experiments. (B) Addition
of hydroxyl function, these fragments bind to the PRDX5 protein. The relative affinity of the fragments derivatives is indicated with (+) signs. (+)
indicated a correct ligand and (+++) a very good ligand.
doi:10.1371/journal.pone.0009744.g008
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15N-HSQC spectrum was collected before
and after each 3D experiment to check the protein stability. A 3D
1H-
15N NOESY-HSQC experiment was also recorded with a
mixing-time of 150 ms. All NMR spectra were processed with
NMRPIPE software [45] and analyzed using NMRView [46].
HSQC experiments
HSQCspectrawere acquired with128 scansand 64 t1 increments
on 550 mlo fu n i f o r m l y
15N-labeled reduced PRDX5 at 100 mMi n
the presence and absence of added compound. Compounds were
tested at 1 mM or 2mM each and binding was analyzed by
monitoring changes in the
15N HSQC spectra. The HSQC spectra
were processed with NMRPIPE software [45] and analyzed using
NMRView [46]. The chemical shift changes were calculated using
the weighted average of the
1Ha n d
15N chemical shift changes DAV
according to the equation DAV=[(Dd
2
H + Dd
2
N/25)/2]
1/2 [47].
Thioredoxin peroxidase activity inhibition assay
Inhibition of thioredoxin peroxidase activity was assayed using
thioredoxin peroxidase assay in a 96-well plate reader essentially as
described by Kim et al. [48] and Theys et al. [49]. Briefly, the
spectrometric assay was performed in a 160 ml reaction mixture
containing 500 mM NADPH, 4 mM recombinant S.cerevisiae
thioredoxin, 2 mM recombinant S.cervisiae thioredoxin reductase,
0.6 mM human recombinant PRDX5 and increasing concentra-
tions (0 to 6 mM) of fragments (from stock solutions in DMSO) in
PBS 0.1M (pH 7.4). The reaction was initiated by adding H2O2 at
the final concentration of 100 mM. NADPH oxidation was
monitored by following absorbance at 340 nm for 30 min at
37uC. The initial rate of reaction was calculated using the linear
portion of the curve and was expressed as the amount of NADPH
oxidized per min. The IC50 was calculated with the percentage of
remaining thioredoxin peroxidase activity. Measurements were
performed in quadruplicates.
Supporting Information Available
Figures showing the chemical shift perturbations of the PRDX5
protein upon addition of fragments, identification of the binding
region for the 6 hit fragments, superposition of the docked
structure of fragment F152 with the X-ray structure of the
benzoate, and the plot of the dose-response relationship of the
inhibition of PRDX5 by F152.
Supporting Information
Figure S1 Chemical shift perturbation of the
15N-HSQC
spectrum of PRDX5 (80 mM) in absence (black contours) and
presence of 1 mM fragment F012 (blue), F090 (red) and F082
(green). The residues that exhibit significant chemical shift
perturbations are labeled according to their sequence-specific
assignment.
Found at: doi:10.1371/journal.pone.0009744.s001 (1.08 MB TIF)
Figure S2 Identification of the binding region of the fragments
into the 3D structure of PRDX5 (1HD2 PDB entry). The four
regions 1 to 4 described in the text are labeled. The chemical shift
variations are mapped into the 3D structure of the protein and
colored in magenta. Proline residues located near the highlighted
region are colored in blue (no NMR data could be obtained due to
the absence of amide proton). In the same way, unassigned
Figure 9. Active site pockets of the three human PRDX groups.
The peroxidatic cysteine is colored in yellow. Aromatic residues are
colored in green, other hydrophobic residues are colored in cyan and
polar residues (Thr, Met) are colored in magenta. Residues that are
located on a protein chain different from the cysteine one are labeled
with the chain name. (PRDX4 is a decamer and PRDX5 and PRDX6 are
dimers). The figure was generated using the PDB structures 2PN8
(PRDX4), 1HD2 (PRDX5) and 1PRX (PRDX6).
doi:10.1371/journal.pone.0009744.g009
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PLoS ONE | www.plosone.org 10 March 2010 | Volume 5 | Issue 3 | e9744residues are colored in green. The peroxidatic cysteine residue is
colored in yellow. (A) fragment F012, (B) fragment F069, (C)
fragment F082, (D) fragment F090, (E) fragment F093 and (F)
fragment F152.
Found at: doi:10.1371/journal.pone.0009744.s002 (1.86 MB TIF)
Figure S3 Superposition of the F152 fragment docked structure
(magenta) with the original X-ray structure for benzoate (yellow)
complexed with PRDX5. The PRDX5 surface is colored according
to the electrostatic potential (red for the negative region, blue for the
positive surface and yellow for the cysteine residue).
Found at: doi:10.1371/journal.pone.0009744.s003 (2.94 MB TIF)
Figure S4 Dose-response relationship of the inhibition of
PRDX5 by F152. The estimated IC50 from this plot is
105+8.5 mM.
Found at: doi:10.1371/journal.pone.0009744.s004 (2.10 MB TIF)
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